Skip to content

Conception Time and Live Birth Outcomes in URSA Patients Undergoing Different Clinical Natural Exposure Pathways: A Single-Center Prospective Real-World Cohort Study

Conception Time and Live Birth Outcomes in URSA Patients Undergoing Different Clinical Natural Exposure Pathways: A Single-Center Prospective Real-World Cohort Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600119082
Enrollment
Unknown
Registered
2026-02-14
Start date
2026-02-15
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unexplained Recurrent Spontaneous Abortion

Interventions

exposed group:None

Sponsors

The first affiliated hostipal of nanchang university
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. A history of >= 2 consecutive spontaneous abortions, meeting the diagnostic criteria for URSA as outlined in the Expert Consensus on the Diagnosis and Treatment of Recurrent Spontaneous Abortion (2022). 2. Age between 18 and 45 years. 3. Planning to conceive naturally or already naturally pregnant with a gestational age <=6 weeks. 4. Completed a standardized etiological workup (including chromosomes, anatomy, coagulation/immunity, endocrinology, infection, male factors, and environmental/psychological factors) with no cause identified. 5. Signed informed consent form.

Exclusion criteria

Exclusion criteria: 1. Presence of a clear, specific etiological factor (e.g., embryonic or parental chromosomal abnormalities, significant uterine malformations, uncontrolled thyroid disease or diabetes, antiphospholipid syndrome (APS), etc.). 2. Comorbidity with severe heart, brain, liver, kidney, hematopoietic, or psychiatric diseases or recent use of potent immunosuppressive agents that could affect the study's outcome assessment. 3. Unwillingness to be followed up or poor anticipated compliance. 4. Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in the study.

Design outcomes

Primary

MeasureTime frame
Time to Pregnancy;live birth;

Secondary

MeasureTime frame
Drug-related adverse events;12 or 24-month cumulative pregnancy rate;

Countries

China

Contacts

Public Contactrui wu

The first affiliated hostipal of nanchang university

tcmclinic@163.com+86 13970997559

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026